Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 7/7/2020
SIETES contiene 93061 citas

 1 a 17 de 17 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi C. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol 2017;83:2605-14. [Ref.ID 102170]
2. Cita con resumen
Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]
Anónimo. Hoquet d'origine médicamenteuse. Prescrire 2008;28:24. [Ref.ID 81927]
Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005;39:128-35. [Ref.ID 72863]
Roberts T G Jr, Chabner BA. Beyond Fast Track for Drug Approvals. N Engl J Med 2004;351:501-5. [Ref.ID 70955]
Anónimo. Réactions cutanées graves et amifostine. Prescrire 2003;23:347. [Ref.ID 65927]
7. Cita con resumen
Zackrisson A-L, Malmström H, Peterson C. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. Eur J Clin Pharmacol 2002;58:103-8. [Ref.ID 61917]
8.Tiene citas relacionadas Cita con resumen
Martin DK, Pater J L, Singer PA. Priority-setting decisions for new cancer drugs: a qualitative case study. Lancet 2001;358:1676-81. [Ref.ID 59944]
9.Tiene citas relacionadas Cita con resumen
Crown J. A "bureausceptic" view of cancer drug rationing. Lancet 2001;358:1660. [Ref.ID 59939]
12. Cita con resumen
Mabro M, Faivre S, Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Saf 1999;21:367-87. [Ref.ID 47690]
Selvaratnam G, Philips R H, Mohamed AK. Cardiotoxicity of cytotoxic chemotherapy and its prevention. Adverse Drug React Toxicol Rev 1999;18:61-105. [Ref.ID 46203]
Links M, Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 1999;57:293-308. [Ref.ID 45119]
Hoekman K, van der Vijgh WJF, Vermoken JB. Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer. Drugs 1999;57:133-55. [Ref.ID 43315]
Cuesta Terán MT, Martínez de la Gándara M, Sierra Bermejo M. Nuevos principios activos: revisión 1996 (1ª parte). Inf Ter Sist Nac Salud 1997;21:11-28. [Ref.ID 33921]
Seleccionar todas
 1 a 17 de 17